Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?